• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Legend Biotech (LEGN) Could Be 60% Undervalued On Fresh CARVYKTI Trial Data

    Simply Wall St·10/06/2026 03:29:40
    Listen to the news

    Legend Biotech (LEGN) put fresh clinical data in front of investors after releasing five year follow up results from its CARTITUDE 2 Cohort A study of CARVYKTI in relapsed or refractory multiple myeloma.

    Legend Biotech’s latest CARVYKTI update lands after a tough stretch for the stock, with the share price falling 32.17% over the past 90 days and the one year total shareholder return down 40.28%. However, the past week’s modest positive share price move hints that sentiment may be stabilising rather than deteriorating further.

    Scan beyond Legend Biotech and see which other cell and oncology players are quietly resetting expectations in our hand picked 19 high quality undiscovered gems.

    The question now is simple but not easy. With Legend Biotech shares down sharply over the past year yet ticking higher in recent days, does it make more sense to step in here, or wait for a cleaner entry before the valuation work begins?

    Most Popular Narrative: 60% Undervalued

    Legend Biotech's most followed valuation story pegs fair value at $46.81 against a last close of $18.78. This points to a wide gap that analysts try to explain through long run growth, margins, and discount rate assumptions.

    Robust innovation pipeline, including next-generation CAR-Ts and in vivo/off-the-shelf cell therapy technologies (e.g., TaVec platform), positions Legend to capitalize on rising demand for advanced, personalized therapies amid secular increases in cancer incidence and sustained healthcare investment, supporting future revenue streams and risk diversification.

    See why 26 investors see Legend Biotech as 60% undervalued.

    The narrative uses a discount rate of 7.62% and ties its $46.81 fair value to projected revenue growth of 19.04% and an 18.60% profit margin. It also relies on a 32.7x future P/E assumption in 2029 and a forecast that earnings move from a loss of $91.5 million to a profit of $399.0 million over that period.

    Analysts in this framework expect Legend Biotech to expand revenue to $2.1b, while also forecasting that the stock would still command a premium multiple versus the wider US Biotechs industry. The same narrative flags that the consensus is not tight, since optimistic forecasts and more cautious views sit far apart, which leaves meaningful room for different interpretations of risk and reward.

    Result: Fair Value of $46.81 (UNDERVALUED)

    Still, the Legend Biotech narrative can unravel if CARVYKTI concentration risk bites or if competitive therapies squeeze the long range opportunity faster than analysts expect.

    Find out about the key risks to this Legend Biotech narrative.

    Next Steps

    Sentiment in the Legend Biotech story is mixed, so treat this as a starting point and move quickly to stress test every assumption for yourself using the 4 key rewards.

    Looking for more Legend Biotech sized opportunities?

    If you stop with Legend Biotech, you risk missing other setups where the numbers quietly line up in your favor and the story has not caught on yet.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.